SCHEMBL2906189

SCHEMBL2906189

N#CCC(=O)OCCN=C=O

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890414 0.79 MCL1 (0.43) MCL1
SCHEMBL11854167 0.78 ADRA2A (0.35)
SCHEMBL21891774 0.78
SCHEMBL2728485 0.76 NAAA (0.45)
SCHEMBL28699927 0.76 DGKA (0.41)
SCHEMBL23231149 0.74 MCL1 (0.40) MCL1
SCHEMBL111548 0.74 ALDH1A1 (0.32)
SCHEMBL20368988 0.74 NAAA (0.41) MCL1
SCHEMBL11662224 0.74
SCHEMBL23130194 0.73 DGKA (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217557-B1 ACTIVATED METHYLENE REAGENTS Henkel IP & Holding GmbH (DE) 2018-01-24 EP disclosed
EP-2217557-B1 ACTIVATED METHYLENE REAGENTS Henkel IP & Holding GmbH (DE) 2018-01-24 EP disclosed
US-20140155556-A1 ADHESIVE SYSTEMS USING IMINES AND SALTS THEREOF, PRECURSORS TO ELECTRON DEFICIENT OLEFINS AND COREACTANTS THEREFOR Henkel IP & Holding GmbH (DE) 2014-06-05 US disclosed
US-20140018487-A1 Adhesive Systems Using Imines and Salts Thereof, Precursors to Electron Deficient Olefins and Coreactants Therefor LOCTITE (R&D) LIMITED (IE) 2014-01-16 US disclosed
US-8481755-B2 Activated methylene reagents and curable compositions prepared therefrom HENKEL IRELAND LTD. (DE) 2013-07-09 US disclosed
US-8481755-B2 Activated methylene reagents and curable compositions prepared therefrom HENKEL IRELAND LTD. (DE) 2013-07-09 US disclosed
EP-2217557-A2 ACTIVATED METHYLENE REAGENTS AND CURABLE COMPOSITIONS PREPARED THEREFROM Loctite (R & D) Limited (IE) 2010-08-18 EP disclosed
US-20100199888-A1 ACTIVATED METHYLENE REAGENTS AND CURABLE COMPOSITIONS PREPARED THEREFROM LOCTITE (R&D) LIMITED (IE) 2010-08-12 US disclosed
US-20100199888-A1 ACTIVATED METHYLENE REAGENTS AND CURABLE COMPOSITIONS PREPARED THEREFROM LOCTITE (R&D) LIMITED (IE) 2010-08-12 US disclosed
WO-2009053482-A2 ACTIVATED METHYLENE REAGENTS AND CURABLE COMPOSITIONS PREPARED THEREFROM LOCTITE (R & D) LIMITED (IE) 2009-04-30 WO disclosed
WO-2009053483-A1 ADHESIVE SYSTEMS USING IMINES AND SALTS THEREOF, PRECURSORS TO ELECTRON DEFICIENT OLEFINS AND COREACTANTS THEREFOR LOCTITE (R & D) LIMITED (IE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100199888-A1 ACTIVATED METHYLENE REAGENTS AND CURABLE COMPOSITIONS PREPARED THEREFROM NOTUM, WASF2, BHMT2 MCL1 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.